Your Health, We Care
Another NameCalquence,Acalanib,康可期,阿可替尼,LuciAcal
IndicationsIt is indicated for the treatment of adult patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).
Reg No.03 L 1314/25
Inspection NO.570-25
CALQUENCE, manufactured by Lucius Pharmaceuticals, is a highly effective BTK inhibitor that demonstrates excellent efficacy and safety, providing patients with a reliable clinical treatment option.
Overview of Key Information About Acalabrutinib
Its main active ingredient is acalabrutinib, which belongs to the class ofBruton's Tyrosine Kinase (BTK) inhibitors.
It is indicated for eligible adult patients with mantle cell lymphoma (MCL),chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).
The recommended dosage is 100 mg taken orally approximately every 12 hours.
It can be administered with or without food.Reference Article: Dosage and Administration of Acalabrutinib
It is contraindicated in pregnant women.
Lactating women should discontinue breastfeeding during treatment.
Patients with severe hepatic impairment should avoid using thismedication.
Specific information on drug overdose has not been clearly documented. If an overdose occurs, medical assistance should be sought immediately.
The medication should be stored at 20°C–25°C, and protected from high temperatures and moisture.
In terms of pharmacokinetics, acalabrutinib is rapidly absorbed after oral administration. It is mainly metabolized by CYP3A, with a relatively short half-life.
FDA，2025.01
